Life Tech to Sequence Breast Cancer Genomes

Xconomy San Diego — 

Life Technologies (NASDAQ: LIFE) the Carlsbad, CA-based maker of gene sequencing instruments and lab supplies, said today it is joining an effort with two partners to sequence the genomes of 14 women with an aggressive form of breast cancer. The partnership, with the Phoenix-based Translational Genomics Research Institute and U.S. Oncology in  Woodands, TX, will sequence the genomes of patients with what is known as “triple-negative” breast cancer, which about one-fifth of women with the disease have, and which doesn’t respond to targeted therapies like Roche’s trastuzumab (Herceptin).

By posting a comment, you agree to our terms and conditions.

Comments are closed.